No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
No Data
Neuphoria Releases Review Of 2024 And Highlights 2025 Plans Including $15M Payment From Merck Extending Company's Cash Runway To Q3 2026 And Phase 3 Affirm-1 Trial of BNC210 In Social Anxiety Disorder Progressing As Planned With Topline Readout...
Neuphoria Provides a Review of 2024 and Highlights 2025 Plans
Express News | Neuphoria Therapeutics Inc : Maxim Group Cuts Target Price to $18 From $48
Neuphoria Therapeutics to Ring the Nasdaq Opening Bell on March 3rd, 2025
Neuphoria Therapeutics | 10-Q: Q2 2025 Earnings Report
Pre-Hour Trading Sees Neuphoria (NEUP) Stock Surge